08:01 AM EDT, 05/05/2025 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) , up 11% in U.S. pre-market trading, on Monday said the three patients that were dosed with the company's lead candidate EP-104GI to treat eosinophilic esophagitis (EoE), continue to experience sustained or improved treatment outcomes after nine months of therapy.

The patients are part of the ongoing Phase 1b/2a Resolve trial.

"EoE is a chronic medical condition and novel treatment options are needed to effectively manage the long-term tissue inflammation and other associated symptoms of EoE," said Dr. Evan Dellon, who chairs Eupraxia's Gastrointestinal Clinical Advisory Board. "The durability in symptom reduction coupled with the prolonged improvement in tissue health from the ongoing RESOLVE trial suggest that EP-104GI could be exerting a tissue remodeling effect on the esophagus."

The company's shares were last seen up US$0.42, to US$4.43, in New York trading.